Entrada Therapeutics insider buys extra 25,000 shares; stake hits 117K
Rhea-AI Filing Summary
On 06/18/2025, Entrada Therapeutics (TRDA) filed a Form 4/A amending its prior insider-trading report. The filing discloses that director Peter S. Kim bought an additional 25,000 common shares on 05/13/2024 at a weighted-average price of $14.6804. This transaction was omitted from the original Form 4 filed on 05/16/2024, which had already reported a separate 25,000-share purchase on 05/14/2024 at $14.5869.
After including both purchases, Kim now directly owns 117,412 TRDA shares. No derivative securities were reported. The amendment corrects share totals and indicates that the director accumulated 50,000 shares over two consecutive trading days, a potential sign of insider confidence despite the minor reporting lapse.
Positive
- Director Peter S. Kim increased his direct stake by 25,000 shares (total 50,000 over two days), bringing holdings to 117,412 shares.
Negative
- The need for an amended filing signals a prior omission, reflecting a minor compliance lapse in insider reporting.
Insights
TL;DR Director’s added 25K-share buy lifts stake to 117,412; insider accumulation is a modestly bullish signal.
The Form 4/A reveals that Peter S. Kim doubled the size of his May 2024 purchase, bringing total buys to 50,000 shares at roughly $14.6 average. While the dollar value is not disclosed, the move raises his direct holding to 117,412 shares, underlining personal conviction in TRDA’s long-term outlook. No sales or derivatives dilute the signal, and the correction itself has no economic impact. Such clustered insider buying is generally viewed favorably by investors seeking alignment between management and shareholder interests.
TL;DR Filing corrects an omission; compliance issue minor, but timeliness of insider reports bears monitoring.
The amendment highlights a procedural oversight—failure to record the 05/13 purchase in the original Form 4. While promptly rectified, repetitive mistakes can raise governance questions. Here, the single error was corrected within regulatory guidelines, and the reporting person reaffirmed willingness to provide pricing details. Overall impact on governance perception is neutral; investors should simply note the need for tighter internal reporting controls.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 25,000 | $14.5869 | $365K |
| Purchase | Common Stock | 25,000 | $14.6804 | $367K |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.465 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
